Investorideas.com

Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS




Share on StockTwits

Pharma Co. Reports Positive Data for Leukemia Combination Therapy

Source: Andrew Fein

 

December 7, 2023 (Investorideas.com Newswire) Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report.


Syros Pharmaceuticals Inc. (SYRS:NASDAQ) announced updated results from the Phase 2 SELECT-AML-1 trial showing its tamibarotene triplet therapy achieved high response rates in relapsed/refractory acute myeloid leukemia (R/R AML), noted H.C. Wainwright analysts Andrew Fein, Dr. Andres Maldonado, Matthew Caufield, and Dr. Ananda Ghosh in a December 6 research report.

Triplet Therapy Shows Further Benefit

The tamibarotene plus venetoclax and azacitidine combination reported a 100% composite complete remission rate, including 78% complete remissions, compared to a 70% rate for the control doublet in 23 patients.

The triplet also led to faster responses than the doublet control.

Analysts View Data as Supportive of Phase 3 Plans

With the triplet continuing to demonstrate greater activity than the current venetoclax/azacitidine standard regimen, the analysts believe Syros is well-positioned to initiate a registrational Phase 3 trial in R/R AML during 2024.

Additional Applications Under Exploration

Beyond AML, Syros is evaluating the tamibarotene triplet in higher-risk myelodysplastic syndrome (MDS), with Phase 3 data expected by mid-2024. The company sees read-through from the latest AML results based on disease similarities.

H.C. Wainwright maintains a Buy rating on Syros with a US$15 price target ahead of multiple clinical catalysts over the next 18 months.

More Info:


Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp


That's all it takes to get an article published on Investor Ideas - Learn More





BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com